LIVIVO - Search results -

Search results

Result 1 - 10 of total 93

Search options

Article ; Online: Prevention of paediatric nosocomial infections: adapting before acting.

Decousser, Jean-Winoc

2017 Volume 17, Issue 4, Page(s) 350–351

MeSH term(s)	Child ; Cross Infection ; Humans
Language	English
Publishing date	2017-01-13
Publishing country	United States
Document type	Journal Article ; Comment
ZDB-ID	2061641-7
ISSN	1474-4457 ; 1473-3099
ISSN (online)	1474-4457
ISSN	1473-3099
DOI	10.1016/S1473-3099(17)30026-9
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5743: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾

Article ; Online: Interactions between Bacteria and

Debourgogne, Anne / Monpierre, Lorra / Sy, Khadeeja Adam / Valsecchi, Isabel / Decousser, Jean-Winoc / Botterel, Françoise

Journal of fungi (Basel, Switzerland)

2023 Volume 9, Issue 9

Abstract: Interactions between different kingdoms of microorganisms in humans are common but not well described. A recent analysis of the mycobiome has described the presence of different fungi and their positive and/or negative interactions with bacteria and ... ...

Abstract	Interactions between different kingdoms of microorganisms in humans are common but not well described. A recent analysis of the mycobiome has described the presence of different fungi and their positive and/or negative interactions with bacteria and other fungi. In chronic respiratory diseases, these different microorganisms form mixed biofilms to live inside. The interactions between Gram-negative bacteria and filamentous fungi in these biofilms have attracted more attention recently. In this review, we analyse the microbiota of the respiratory tract of healthy individuals and patients with chronic respiratory disease. Additionally, we describe the regulatory mechanisms that rule the mixed biofilms of
Language	English
Publishing date	2023-09-01
Publishing country	Switzerland
Document type	Journal Article ; Review
ZDB-ID	2784229-0
ISSN	2309-608X ; 2309-608X
ISSN (online)	2309-608X
ISSN	2309-608X
DOI	10.3390/jof9090900
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: A Selective Culture Medium for Screening Cefiderocol Resistance in

Ibrahim, Ahmad / Bouvier, Maxime / Sadek, Mustafa / Decousser, Jean-Winoc / Poirel, Laurent / Nordmann, Patrice

Journal of clinical microbiology

2023 Volume 61, Issue 7, Page(s) e0188322

Abstract: Cefiderocol (FDC) is a siderophore cephalosporin with a broad spectrum of activity against many multidrug-resistant Gram-negative bacteria. Acquired resistance to FDC has been already reported among Gram-negative isolates, thus highlighting the need for ... ...

Abstract	Cefiderocol (FDC) is a siderophore cephalosporin with a broad spectrum of activity against many multidrug-resistant Gram-negative bacteria. Acquired resistance to FDC has been already reported among Gram-negative isolates, thus highlighting the need for rapid and accurate identification of such resistant pathogens, in order to control their spread. Therefore, the SuperFDC medium was developed to screen FDC-resistant
MeSH term(s)	Humans ; Anti-Bacterial Agents/pharmacology ; Pseudomonas aeruginosa ; Acinetobacter baumannii ; Gram-Negative Bacteria ; Cephalosporins/pharmacology ; Microbial Sensitivity Tests ; Drug Resistance, Multiple, Bacterial ; Cefiderocol
Chemical Substances	Anti-Bacterial Agents ; Cephalosporins
Language	English
Publishing date	2023-06-20
Publishing country	United States
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	390499-4
ISSN	1098-660X ; 0095-1137
ISSN (online)	1098-660X
ISSN	0095-1137
DOI	10.1128/jcm.01883-22
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1188: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Evaluation of in vitro pharmacodynamic drug interactions of ceftazidime/avibactam and fosfomycin in Escherichia coli.

Kroemer, Niklas / Martens, Miklas / Decousser, Jean-Winoc / Grégoire, Nicolas / Nordmann, Patrice / Wicha, Sebastian G

The Journal of antimicrobial chemotherapy

2023 Volume 78, Issue 10, Page(s) 2524–2534

Abstract: Background: Combination therapy can increase efficacy of antibiotics and prevent emergence of resistance. Ceftazidime/avibactam and fosfomycin may be empirically combined for this purpose, but a systematic and quantitative evaluation of this combination ...

Abstract	Background: Combination therapy can increase efficacy of antibiotics and prevent emergence of resistance. Ceftazidime/avibactam and fosfomycin may be empirically combined for this purpose, but a systematic and quantitative evaluation of this combination is needed. Objectives: In this study, a systematic analysis of the pharmacodynamic interactions of ceftazidime/avibactam and fosfomycin in clinical and isogenic Escherichia coli strains carrying genes coding for several carbapenemases or ESBLs was performed and pharmacodynamic interactions were quantified by modelling and simulations. Methods: Pharmacodynamic interactions were evaluated in 'dynamic' chequerboard experiments with quantification of viable bacteria in eight isogenic and six clinical E. coli strains. Additionally, supplemental time-kill experiments were performed and genomic analyses were conducted on representative fosfomycin-resistant subpopulations. Models were fitted to all data using R and NONMEM®. Results: Synergistic drug interactions were identified for 67% of the clinical and 75% of the isogenic isolates with a mean EC50 reduction of >50%. Time-kill experiments confirmed the interactions and modelling quantified EC50 reductions up to 97% in combination and synergy prevented regrowth of bacteria by enhanced killing effects. In 9 out of 12 fosfomycin-resistant mutants, genomic analyses identified previously reported mutations. Conclusions: The broad synergistic in vitro activity of ceftazidime/avibactam and fosfomycin confirms the potential of the application of this drug combination in clinics. The substantial reduction of the EC50 in combination may allow use of lower doses or treatment of organisms with higher MIC values and encourage further research translating these findings into the clinical setting.
MeSH term(s)	Ceftazidime/pharmacology ; Fosfomycin/pharmacology ; Escherichia coli/genetics ; Drug Synergism ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Azabicyclo Compounds/pharmacology ; Drug Combinations ; beta-Lactamases/genetics ; Drug Interactions ; Microbial Sensitivity Tests
Chemical Substances	Ceftazidime (9M416Z9QNR) ; Fosfomycin (2N81MY12TE) ; avibactam (7352665165) ; Anti-Bacterial Agents ; Azabicyclo Compounds ; Drug Combinations ; beta-Lactamases (EC 3.5.2.6)
Language	English
Publishing date	2023-08-25
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't
ZDB-ID	191709-2
ISSN	1460-2091 ; 0305-7453
ISSN (online)	1460-2091
ISSN	0305-7453
DOI	10.1093/jac/dkad264
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1197: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 124: Show issues

Order via subito

Details ▾

Article ; Online: Rapid detection of cefiderocol susceptibility/resistance in Acinetobacter baumannii.

Raro, Otávio Hallal Ferreira / Bouvier, Maxime / Kerbol, Auriane / Decousser, Jean-Winoc / Poirel, Laurent / Nordmann, Patrice

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology

2023 Volume 42, Issue 12, Page(s) 1511–1518

Abstract: Purpose: Due to its ability to disseminate worldwide and its multiple resistance trait, Acinetobacter baumannii is becoming a threat for public health worldwide. Cefiderocol (FDC) is a promising broad-spectrum cephalosporin recently approved for ... ...

Abstract	Purpose: Due to its ability to disseminate worldwide and its multiple resistance trait, Acinetobacter baumannii is becoming a threat for public health worldwide. Cefiderocol (FDC) is a promising broad-spectrum cephalosporin recently approved for treating Gram-negative infection. The aim of this study was to develop a rapid test, namely the rapid FDC Acinetobacter baumannii NP test, for the detection of FDC susceptibility/resistance in A. baumannii since the current FDC susceptibility tests are rather time-consuming (at least 24 h). Materials and methods: The rapid test is based on the reduction of resazurin to resorufin product by bacterial viable cells, thus detecting bacterial growth in the presence of FDC (38.4 mg/L). A color change from blue (resazurin) to violet or pink (resorufin) represents visual detection of bacterial growth. 95 randomly selected A. baumannii isolates were used to evaluate the performance of the rapid FDC Acinetobacter baumannii NP test. Results: The test showed 95.5% (95% CI 78.2-99.2%) and 100.0% (95% CI 95.0-100.0%) of sensitivity and specificity, respectively. All the results were obtained within 4 h30-4 h45 incubation time at 35 °C ± 2 °C, saving virtually one day when compared with currently-used antimicrobial susceptibility tests. The test showed only a single very major error, an isolate with a MIC of 8 mg/L. Conclusions: The rapid FDC Acinetobacter baumannii NP test can be a valuable method which is easier and faster to interpret when compared with the gold standard broth microdilution method. The test showed remarkable performances; hence, it may be suitable for implementation in clinical microbiology routine laboratories.
MeSH term(s)	Humans ; Anti-Bacterial Agents/pharmacology ; Acinetobacter baumannii ; Drug Resistance, Multiple, Bacterial ; Cephalosporins/pharmacology ; Microbial Sensitivity Tests ; Cefiderocol
Chemical Substances	Anti-Bacterial Agents ; Cephalosporins
Language	English
Publishing date	2023-11-01
Publishing country	Germany
Document type	Journal Article
ZDB-ID	603155-9
ISSN	1435-4373 ; 0934-9723 ; 0722-2211
ISSN (online)	1435-4373
ISSN	0934-9723 ; 0722-2211
DOI	10.1007/s10096-023-04691-w
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1732: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Biobased polymer resources and essential oils: a green combination for antibacterial applications.

Elian, Christine / Andaloussi, Samir Abbad / Moilleron, Régis / Decousser, Jean-Winoc / Boyer, Cyrille / Versace, Davy-Louis

Journal of materials chemistry. B

2022 Volume 10, Issue 44, Page(s) 9081–9124

Abstract: To fight nosocomial infections, the excessive use of antibiotics has led to the emergence of multidrug-resistant microorganisms, which are now considered a relevant public health threat by the World Health Organization. To date, most antibacterial ... ...

Abstract	To fight nosocomial infections, the excessive use of antibiotics has led to the emergence of multidrug-resistant microorganisms, which are now considered a relevant public health threat by the World Health Organization. To date, most antibacterial systems are based on the use of petro-sourced polymers, but the global supplies of these resources are depleting. Besides, silver NPs are widely accepted as the most active biocide against a wide range of bacterial strains but their toxicity is an issue. The growing interest in natural products has gained increasing interest in the last decade. Therefore, the design of functional antibacterial materials derived from biomass remains a significant challenge for the scientific community. Consequently, attention has shifted to naturally occurring substances such as essential oils (EOs), which are classified as Generally Recognized as Safe (GRAS). EOs can offer an alternative to the common antimicrobial agents as an inner solution or biocide agent to inhibit the resistance mechanism. Herein, this review not only aims at providing developments in the antibacterial modes of action of EOs against various bacterial strains and the recent advances in genomic and proteomic techniques for the elucidation of these mechanisms but also presents examples of biobased polymer resource-based EO materials and their antibacterial activities. Especially, we describe the antibacterial properties of biobased polymers,
MeSH term(s)	Oils, Volatile/pharmacology ; Microbial Sensitivity Tests ; Polymers/pharmacology ; Proteomics ; Anti-Bacterial Agents/pharmacology ; Bacteria ; Disinfectants
Chemical Substances	Oils, Volatile ; Polymers ; Anti-Bacterial Agents ; Disinfectants
Language	English
Publishing date	2022-11-16
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2702241-9
ISSN	2050-7518 ; 2050-750X
ISSN (online)	2050-7518
ISSN	2050-750X
DOI	10.1039/d2tb01544g
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Pharmacokinetic/pharmacodynamic analysis of ceftazidime/avibactam and fosfomycin combinations in an

Kroemer, Niklas / Amann, Lisa F / Farooq, Aneeq / Pfaffendorf, Christoph / Martens, Miklas / Decousser, Jean-Winoc / Grégoire, Nicolas / Nordmann, Patrice / Wicha, Sebastian G

Microbiology spectrum

2023 Volume 12, Issue 1, Page(s) e0331823

Abstract: Importance: Mechanistic understanding of pharmacodynamic interactions is key for the development of rational antibiotic combination therapies to increase efficacy and suppress the development of resistances. Potent tools to provide those insights into ... ...

Abstract	Importance: Mechanistic understanding of pharmacodynamic interactions is key for the development of rational antibiotic combination therapies to increase efficacy and suppress the development of resistances. Potent tools to provide those insights into pharmacodynamic drug interactions are semi-mechanistic modeling and simulation techniques. This study uses those techniques to provide a detailed understanding with regard to the direction and strength of the synergy of ceftazidime-avibactam and ceftazidime-fosfomycin in a clinical
MeSH term(s)	Ceftazidime/pharmacology ; Ceftazidime/therapeutic use ; Fosfomycin/pharmacology ; Escherichia coli/genetics ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; beta-Lactamases/genetics ; Microbial Sensitivity Tests ; Drug Combinations ; Azabicyclo Compounds
Chemical Substances	avibactam, ceftazidime drug combination ; Ceftazidime (9M416Z9QNR) ; Fosfomycin (2N81MY12TE) ; avibactam (7352665165) ; Anti-Bacterial Agents ; beta-Lactamases (EC 3.5.2.6) ; Drug Combinations ; Azabicyclo Compounds
Language	English
Publishing date	2023-12-08
Publishing country	United States
Document type	Journal Article
ZDB-ID	2807133-5
ISSN	2165-0497 ; 2165-0497
ISSN (online)	2165-0497
ISSN	2165-0497
DOI	10.1128/spectrum.03318-23
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Late-onset ventilator-associated pneumonia due to

Royer, Guilhem / Lecorche, Emmanuel / Sakr, Céline / Cizeau, Florence / Ducellier, David / Fihman, Vincent / Razazi, Keyvan / Woerther, Paul-Louis / Decousser, Jean-Winoc

Infection control and hospital epidemiology

2023 Volume 45, Issue 3, Page(s) 402–403

MeSH term(s)	Humans ; Mycobacterium chelonae ; Pneumonia, Ventilator-Associated/diagnosis ; Pneumonia, Ventilator-Associated/drug therapy ; Mycobacterium Infections, Nontuberculous/diagnosis ; Mycobacterium Infections, Nontuberculous/microbiology ; Anti-Bacterial Agents/therapeutic use
Chemical Substances	Anti-Bacterial Agents
Language	English
Publishing date	2023-11-03
Publishing country	United States
Document type	Journal Article
ZDB-ID	639378-0
ISSN	1559-6834 ; 0195-9417 ; 0899-823X
ISSN (online)	1559-6834
ISSN	0195-9417 ; 0899-823X
DOI	10.1017/ice.2023.119
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1714: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: An improved PKPD modeling approach to characterize the pharmacodynamic interaction over time between ceftazidime/avibactam and colistin from

Aubry, Romain / Buyck, Julien / Prouvensier, Laure / Decousser, Jean-Winoc / Nordmann, Patrice / Wicha, Sebastian G / Marchand, Sandrine / Grégoire, Nicolas

Antimicrobial agents and chemotherapy

2023 Volume 67, Issue 10, Page(s) e0030123

Abstract: In contrast to the checkerboard method, bactericidal experiments [time-kill curves (TKCs)] allow an assessment of pharmacodynamic (PD) interactions over time. However, TKCs in combination pose interpretation problems. The objective of this study was to ... ...

Abstract	In contrast to the checkerboard method, bactericidal experiments [time-kill curves (TKCs)] allow an assessment of pharmacodynamic (PD) interactions over time. However, TKCs in combination pose interpretation problems. The objective of this study was to characterize the PD interaction over time between ceftazidime/avibactam (CZA) and colistin (CST) using TKC against four multidrug-resistant
MeSH term(s)	Humans ; Ceftazidime/pharmacology ; Colistin/pharmacology ; Klebsiella pneumoniae ; Anti-Bacterial Agents/therapeutic use ; Azabicyclo Compounds/pharmacology ; Drug Combinations ; beta-Lactamases/pharmacology ; Microbial Sensitivity Tests ; Klebsiella Infections/drug therapy
Chemical Substances	Ceftazidime (9M416Z9QNR) ; Colistin (Z67X93HJG1) ; avibactam (7352665165) ; Anti-Bacterial Agents ; Azabicyclo Compounds ; Drug Combinations ; beta-Lactamases (EC 3.5.2.6)
Language	English
Publishing date	2023-09-08
Publishing country	United States
Document type	Journal Article
ZDB-ID	217602-6
ISSN	1098-6596 ; 0066-4804
ISSN (online)	1098-6596
ISSN	0066-4804
DOI	10.1128/aac.00301-23
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 809: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Einzelsignatur: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Pharmacokinetic/pharmacodynamic evaluation of tigecycline dosing in a hollow fiber infection model against clinical bla-KPC producing Klebsiella Pneumoniae isolates.

Amann, Lisa F / Broeker, Astrid / Riedner, Maria / Rohde, Holger / Huang, Jiabin / Nordmann, Patrice / Decousser, Jean-Winoc / Wicha, Sebastian G

Diagnostic microbiology and infectious disease

2023 Volume 108, Issue 2, Page(s) 116153

Abstract: The FDA announced a boxed warning for tigecycline due to progression of infections caused by Gram-negative bacteria and increased risk of mortality during treatment. Plasma exposure of tigecycline might not prevent bacteraemia in these cases from the ... ...

Abstract	The FDA announced a boxed warning for tigecycline due to progression of infections caused by Gram-negative bacteria and increased risk of mortality during treatment. Plasma exposure of tigecycline might not prevent bacteraemia in these cases from the focuses. Hence, we evaluated intensified dosing regimens and breakpoints that might suppress bloodstream infections, caused by progression of infection by e.g., Gram-negatives. A pharmacometric model was built from tigecycline concentrations (100-600 mg daily doses) against clinical Klebsiella pneumoniae isolates (MIC 0.125-0.5 mg/L). Regrowth occurred at clinically used doses and stasis was only achieved with 100 mg q8h for the strain with the lowest studied MIC of 0.125 mg/L. Stasis at 24 h was related to fAUC/MIC of 38.5. Our study indicates that even intensified dosing regimens might prevent bloodstream infections only for MIC values ≤0.125 mg/L for tigecycline. This indicates an overly optimistic breakpoint of 1 mg/L for Enterobacterales, which are deemed to respond to the tigecycline high dose regimen (EUCAST Guidance Document on Tigecycline Dosing 2022).
MeSH term(s)	Humans ; Tigecycline ; Anti-Bacterial Agents/pharmacology ; Anti-Bacterial Agents/therapeutic use ; Klebsiella pneumoniae ; Minocycline/pharmacology ; Minocycline/therapeutic use ; Bacteremia/drug therapy ; Microbial Sensitivity Tests ; beta-Lactamases
Chemical Substances	Tigecycline (70JE2N95KR) ; Anti-Bacterial Agents ; Minocycline (FYY3R43WGO) ; beta-Lactamases (EC 3.5.2.6)
Language	English
Publishing date	2023-11-30
Publishing country	United States
Document type	Journal Article
ZDB-ID	604920-5
ISSN	1879-0070 ; 0732-8893
ISSN (online)	1879-0070
ISSN	0732-8893
DOI	10.1016/j.diagmicrobio.2023.116153
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 1845: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

To top

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito